
Arrowhead Pharmaceuticals Secures Health Canada Approval for REDEMPLO™ (plozasiran) to Treat Adults with Familial Chylomicronemia Syndrome (FCS)
Arrowhead Pharmaceuticals, Inc. announced that Health Canada has granted approval for REDEMPLO™ (plozasiran) as a treatment to reduce triglyceride lev...















































